Protagonist Therapeutics (PTGX) Price & Analysis

Compare

729 Followers

PTGX Stock Chart & Stats

$87.41

-$0.87(-2.26%)

At close: Jan 08 4:00 PM EST

$87.41

-$0.87(-2.26%)

Day’s Range― - ―

52-Week Range$33.70 - $96.54

Previous CloseN/A

Volume120.35K

Average Volume (3M)995.51K

Market Cap

$5.46B

Enterprise Value$3.67B

Total Cash (Recent Filing)$576.12M

Total Debt (Recent Filing)$10.75M

Price to Earnings (P/E)140.1

Beta0.27

Next Earnings

Mar 18, 2026

EPS Estimate

-0.34

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.62

Shares Outstanding62,515,667

10 Day Avg. Volume1,212,450

30 Day Avg. Volume995,508

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)3.52

Price to Sales (P/S)5.47

P/FCF Ratio13.00

Enterprise Value/Market Cap0.67

Enterprise Value/Revenue17.55

Enterprise Value/Gross Profit17.55

Enterprise Value/Ebitda133.35

Forecast

1Y Price Target

$93.25

Price Target Upside6.68% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-1.65

Revenue Forecast (FY)$64.52M

Bulls Say, Bears Say

Bulls Say

Efficacy And Safety ProfileRusfertide demonstrated a safety profile similar to placebo, with a high compliance rate supporting its appealing clinical profile.

Potential AcquisitionThere is potential for a significant acquisition similar to Novartis' recent acquisition of Avidity Biosciences, with ongoing discussions between JNJ and PTGX.

Regulatory ProgressThe NDA submission for rusfertide and oral hepcidin candidate nomination remain on track for the fourth quarter of 2025.

Bears Say

Protagonist Therapeutics News

Protagonist Therapeutics price target raised to $108 from $88 at Barclays

Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $108 from $88 and keeps an Overweight...

7d ago

PTGX

Protagonist Therapeutics price target raised to $115 from $98 at Citi

Citi raised the firm’s price target on Protagonist Therapeutics (PTGX) to $115 from $98 and keeps a Buy...

16d ago

PTGX

Protagonist, Takeda present longer-term data at ASH 2025 on rusfertide

Protagonist Therapeutics (PTGX) and Takeda (TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study...

17d ago

TAK

PTGX

Promising Clinical Data and Strategic Collaborations Drive Buy Rating for Protagonist Therapeutics

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on Protagonist Therapeutics, with a...

16d ago

PTGX

Protagonist Therapeutics price target raised to $65 from $47 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Protagonist Therapeutics (PTGX) to $65 from $47 and keeps a...

1M ago

PTGX

Protagonist Therapeutics price target raised to $98 from $96 at Citi

Citi raised the firm’s price target on Protagonist Therapeutics (PTGX) to $98 from $96 and keeps a Buy...

1M ago

PTGX

Protagonist Therapeutics price target raised to $81 from $68 at JPMorgan

JPMorgan analyst Brian Cheng raised the firm’s price target on Protagonist Therapeutics (PTGX) to $81 from $68 and...

2M ago

PTGX

Protagonist Therapeutics price target raised to $88 from $72 at Barclays

Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $88 from $72 and keeps an Overweight...

2M ago

PTGX

Protagonist Therapeutics price target raised to $102 from $69 at Citizens JMP

Citizens JMP raised the firm’s price target on Protagonist Therapeutics (PTGX) to $102 from $69 and keeps an...

2M ago

PTGX

Protagonist Therapeutics price target raised to $91 from $74 at Clear Street

Clear Street raised the firm’s price target on Protagonist Therapeutics (PTGX) to $91 from $74 and keeps a...

2M ago

PTGX

Protagonist Therapeutics Advances Pipeline Amid Financial Loss

Protagonist Therapeutics Inc ( ($PTGX) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

PTGX

Promising Developments and Strategic Progress at Protagonist Therapeutics Drive Buy Rating

Protagonist Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tara Bancroft from...

2M ago

PTGX

Protagonist Therapeutics reports Q3 EPS (62c), consensus (64c)

Reports Q3 revenue $4.71M, consensus $4.14M. “2025 continues to be a highly productive year with significant accomplishments in...

2M ago

PTGX

PTGX Earnings this Week: How Will it Perform?

Protagonist Therapeutics Inc (PTGX) is scheduled to report 3rd quarter earnings on 11/05/2025. Regarding Q3 estimates, Wall Street...

2M ago

PTGX

PTGX FAQ

What was Protagonist Therapeutics Inc’s price range in the past 12 months?

Protagonist Therapeutics Inc lowest stock price was $33.70 and its highest was $96.54 in the past 12 months.

What is Protagonist Therapeutics Inc’s market cap?

Protagonist Therapeutics Inc’s market cap is $5.46B.

When is Protagonist Therapeutics Inc’s upcoming earnings report date?

Protagonist Therapeutics Inc’s upcoming earnings report date is Mar 18, 2026 which is in 84 days.

How were Protagonist Therapeutics Inc’s earnings last quarter?

Protagonist Therapeutics Inc released its earnings results on Nov 06, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.612 by -$0.008.

Is Protagonist Therapeutics Inc overvalued?

According to Wall Street analysts Protagonist Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Protagonist Therapeutics Inc pay dividends?

Protagonist Therapeutics Inc does not currently pay dividends.

What is Protagonist Therapeutics Inc’s EPS estimate?

Protagonist Therapeutics Inc’s EPS estimate is -0.34.

How many shares outstanding does Protagonist Therapeutics Inc have?

Protagonist Therapeutics Inc has 62,515,667 shares outstanding.

What happened to Protagonist Therapeutics Inc’s price movement after its last earnings report?

Protagonist Therapeutics Inc reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.612. Following the earnings report the stock price went down -0.301%.

Which hedge fund is a major shareholder of Protagonist Therapeutics Inc?

Currently, no hedge funds are holding shares in PTGX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Protagonist Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

7.80%

Trailing 12-Months

Asset Growth

16.20%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Protagonist Therapeutics Inc

Protagonist Therapeutics (PTGX) is a biopharmaceutical company focused on the discovery and development of novel peptide-based therapeutics for the treatment of serious diseases, particularly in the areas of gastrointestinal and autoimmune disorders. The company utilizes its proprietary technology platform to design and develop selective peptide therapeutics that target specific pathways in the human body, with a strong emphasis on precision medicine. PTGX's core product candidates include treatments for conditions such as ulcerative colitis and Crohn's disease, aiming to provide effective and safer alternatives to existing therapies.

Protagonist Therapeutics (PTGX) Earnings & Revenues

Historic Earnings Reports

PTGX Stock 12 Month Forecast

Average Price Target

$93.25

▲(6.68% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"36":"$36","56":"$56","76":"$76","96":"$96","116":"$116"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":93.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$93.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[36,56,76,96,116],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.64,87.89846153846153,90.15692307692308,92.41538461538461,94.67384615384616,96.93230769230769,99.19076923076923,101.44923076923077,103.70769230769231,105.96615384615384,108.22461538461539,110.48307692307692,112.74153846153845,{"y":115,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.64,86.22538461538461,86.81076923076922,87.39615384615385,87.98153846153846,88.56692307692308,89.15230769230769,89.73769230769231,90.32307692307693,90.90846153846154,91.49384615384615,92.07923076923078,92.66461538461539,{"y":93.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.64,84.05230769230769,82.46461538461539,80.87692307692308,79.28923076923077,77.70153846153846,76.11384615384615,74.52615384615385,72.93846153846154,71.35076923076923,69.76307692307692,68.17538461538462,66.58769230769231,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":43.26,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.21,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.62,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.64,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >